ClinicalTrials.gg

Program

afimetoran

Also written as “BMS-986256” and “Afimetoran”.

Its studies are mostly in Lupus Erythematosus, Cutaneous · Lupus Erythematosus, Systemic, led by 2 companies.

Furthest: phase 3, since Aug 15, 201812 company-led studies, 2 open or runningNext primary completion: Apr 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb100 open or runningphase 1since Aug 15, 2018Aug 15, 2018none ahead
Beeline Medicines22 open or runningphase 3since Oct 5, 2026May 19, 2021Apr 2030phase 3 · NCT07881120

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 15, 2018First study: phase 1 study in Healthy ParticipantsNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT03634995 · 118 enrolled · United States
  2. May 14, 2019Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT03950960 · 15 enrolled · United States
  3. Jun 26, 2019Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT04016753 · 32 enrolled · United States
  4. Jul 22, 2019Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT04039373 · 15 enrolled · United States
  5. Feb 12, 2020Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT04269356 · 8 enrolled · United States
  6. Jul 13, 20202 phase 1 studiesBristol-Myers Squibb · NCT04470778, NCT04493541
  7. May 19, 2021Beeline Medicines's first study: phase 2 study in Lupus Erythematosus, SystemicNew to Beeline MedicinesBeeline Medicines · NCT04895696 · 248 enrolled · United States, Argentina, Australia and more
  8. Jun 24, 2021Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT04941755 · 22 enrolled · United States
  9. May 10, 2023Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT05866627 · 32 enrolled · United Kingdom
  10. Jun 5, 2023Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT05901714 · 65 enrolled · United States
  11. Oct 5, 2026Phase 3 study in Lupus Erythematosus, CutaneousPhase 3 reachedBeeline Medicines · NCT07881120 · 390 planned · United States

Ahead

  1. Apr 2030Primary completion: phase 3 study in Lupus Erythematosus, CutaneousBeeline Medicines · NCT07881120

TargetBeta

TLR7 →TLR8 →read by rule
“Toll-like receptor 8 inhibitor; Toll-like receptor 7 inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
resiquimodruleStaidson (Beijing) Biopharmaceuticalsphase 314
enpatoranruleMerck KGaA, Darmstadt, Germanyphase 312

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07881120Lupus Erythematosus, Cutaneous · United States3RecruitingBeeline MedicinesApr 2030390
NCT05901714Healthy Participants · United States1CompletedBristol-Myers SquibbApr 11, 202465
NCT05866627Healthy Volunteers · United Kingdom1CompletedBristol-Myers SquibbSep 29, 202332
NCT04941755Healthy Participants · United States1CompletedBristol-Myers SquibbSep 24, 202122
NCT04895696Lupus Erythematosus, Systemic · United States, Argentina, Australia and more2Active, not recruitingBeeline MedicinesJun 12, 2026248
NCT04493541Lupus Erythematosus, Cutaneous · Germany1CompletedBristol-Myers SquibbApr 21, 202313
NCT04470778Healthy Participants · United States1CompletedBristol-Myers SquibbMar 21, 202135
NCT04269356Healthy Participants · United States1CompletedBristol-Myers SquibbMar 30, 20218
NCT04039373Healthy Participants · United States1CompletedBristol-Myers SquibbSep 18, 201915
NCT04016753Healthy Participants · United States1CompletedBristol-Myers SquibbFeb 21, 202032
NCT03950960Healthy Participants · United States1CompletedBristol-Myers SquibbJul 31, 201915
NCT03634995Healthy Participants · United States1CompletedBristol-Myers SquibbOct 9, 2019118

How it is read

Names in the registry

  • “BMS-986256”, 8 entries
  • “Afimetoran”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.